TVP-1012 1mg ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	3

6. パーキンソン病

---

臨床試験数 : 2,298 /  薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02337751 (ClinicalTrials.gov)	July 10, 2015	9/1/2015	A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants	A Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa	Parkinson's Disease	Drug: TVP-1012 1mg	Takeda	NULL	Completed	30 Years	79 Years	All	198	Phase 3	Japan
2	NCT02337764 (ClinicalTrials.gov)	February 3, 2015	9/1/2015	A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants	A Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients	Parkinson's Disease	Drug: TVP-1012 1mg	Takeda	NULL	Completed	30 Years	79 Years	All	222	Phase 3	Japan
3	NCT02337738 (ClinicalTrials.gov)	January 27, 2015	9/1/2015	A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing Off	Parkinson's Disease	Drug: TVP-1012 1mg;Drug: TVP-1012 0.5mg;Drug: Placebo	Takeda	NULL	Completed	30 Years	79 Years	All	404	Phase 2/Phase 3	Japan